US-based brain-computer interface (BCI) company Synchron has announced the integration of generative AI into its brain implant interface system that allows people living with disabilities to non-verbally interact with screens. But can produce text quickly and easily. First
Using OpenAI's Multimodal Generative Pre-Training Transformer (GPT), Synchron says the BCI Chat feature can now allow users to generate automated prompts for texting and chatting, including context and user sentiment. Classified by contextual input.
Designed to help people living with conditions such as amyotrophic lateral sclerosis (ALS), the Synchron BCI is implanted into a blood vessel at the level of the brain's motor cortex in what the company calls a minimally invasive procedure. Describes as The radio device then transmits the signals from the brain into a wireless signal picked up by the desktop device.
Using OpenAI's GPT system, Synchron claims the system can generate text or audio based on user input at the speed of normal human conversation.
Additionally, the company adds that input users generate will not be directly shared or stored with OpenAI.
Tom Oxley, CEO and founder of Synchron, said: “Our users have lost the ability to make choices due to neurological disorders. Generative AI can make predictions that are relevant to your environment, and BCI can make individual choices. Enables
Access the most comprehensive company profiles on the market, powered by GlobalData. Save hours of research. Gain a competitive edge.
Company Profile – Free Sample
Your download email will arrive shortly.
We believe in the unique quality of our company profiles. However, we want you to make the best decision for your business, so we offer a free sample that you can download by submitting the form below.
By Global Data
“BCIs protect and extend a fundamental human right: freedom of expression. We embrace our autonomy until it is lost. This is a pivotal moment in the union of powerful technologies that can restore lives.” can do.”
BCI and neuromodulation technologies are evolving rapidly. A model by GlobalData estimates that the global neuromodulation device market will be worth $11.4 billion by 2033, up from $6 billion in 2022. The announcement comes after Synchron was able to acquire an equity stake in Acquandas, a supplier of high-precision equipment, for an undisclosed sum. Amount in February this year.
Elsewhere in the field of brain-computer interfaces, US-based Neuralink reported an unexpected setback with its first chip implanted in a human skull, when the device began to detach from the patient's brain.